Analysis of prognostic factors of primary gastrointestinal diffuse large B-cell lymphoma

王洁琼,韩晓凤,肖菲,黄洪晖,王婷,钟璐,徐岚,陈芳源
DOI: https://doi.org/10.16138/j.1673-6087.2015.01.005
2015-01-01
Abstract:Objective To analyze the clinical features,cell origin, and the therapy that affects the prognosis of primary gastrointestinal diffuse large B cell lymphoma(PGI-DLBCL). Methods Clinic data of 91 patients with PGI-DLBCL hospitalized in Renji hospital from April 2000 to June 2014 were analyzed retrospectively. Results The follow-up ranged from 3 to 166 months, with a median of 49 months. Of the 91 patients, the ratio of male to female was 1.22 ∶1, the median age was 57(17-79) years; 49 cases(53.8%) were Ann Arbor stage Ⅰ-Ⅱ, 42 cases(46.2%)were stage Ⅲ-Ⅳ; 73 cases(80.2%)were international prognostic index(IPI) 0-2 scores and 18 cases(19.8%)were 3-5 scores. Among the 63 cases categorized by Hanu0027s classification, 22 cases(34.9%) were germinal center B cell-like(GCB) and 41 cases(65.1%) were non-GCB. Fifty five patients(60.4%) were treated with CHOP(cyclophosphamide, vindesine, epirubicin,methylprednisolone), and the other 36 patients(39.6%) were treated with R-CHOP(rituximab plus CHOP), and the overall5-year survival rate were 75.5% and 95.7%, respectively. The analysis of prognosis showed that the Ann Arbor stage, IPI,serum lactate dehydrogenase(LDH), immunological subgroup and R-CHOP immunochemotherapy were the independent prognostic factors(all P0.05). Conclusions The Ann Arbor stage, IPI score, serum level of lactic dehydrogenase, R-CHOP immunochemotherapy and immunological subgroup were the factors significantly associated with prognosis of PGI-DLBCL.
What problem does this paper attempt to address?